Kathleen Moore, MD, discusses findings compiled from 3 clinical trials of niraparib in patients with ovarian cancer.
At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Kathleen Moore, MD, director of the Oklahoma TSET Phase I Program and an associate professor of the Section of Gynecologic Oncology at The University of Oklahoma College of Medicine, to discuss key takeaways from 3 clinical trials that examined niraparib (Zejula) in BRCA-mutant ovarian cancer.
The analysis assessed the results of the phase 3 PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016), ENGOT-OV16/NOVA (NCT01847274), and NORA (NCT03705156) trials, which examined the use of maintenance niraparib in the frontline and later-line settings of advanced ovarian, fallopian tube, or primary peritoneal cancer.
We are looking at 3 relatively large studies. We are a talking about approximately 1500 women who participated in PRIMA in the frontline, and NOVA and NORA in the [later]-line [setting]. About 1000 patients were treated with niraparib. One of the take-home [messages] is that we do not see any big or meaningful differences in terms of the toxicity profile when you move PARP [inhibitors] to the frontline, as opposed to using [them] as second-line maintenance. That is important. Safety is important in both settings. But it is important because in the frontline, we still do have the potential to cure. Carboplatin alone has an unacceptably low, but present, rate of long-term [median] disease-free survival of 7 to 10 years for advanced stage of cancer.
Gonzalez Martin A, Matulonis UA, Korach J, et al. Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: results from three phase 3 niraparib trials. J Clin Oncol. 2021;39(suppl 15):5518. doi:10.1200/JCO.2021.39.15_suppl.5518